Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Calcium, Phosphate and Skeletal Demands in Pregnancy: Full Evidence Review

Previous related pageVitamin D, Calcium, Phosphate and Skeletal Demands in Pregnancy: Study SummaryNext related pageHow to Read Vitamin D Studies During Pregnancy
Study at a glance

What was the question?

How does vitamin D relate to calcium, phosphate and bone demands during pregnancy? The review separates blood concentrations from mineral absorption, kidney losses and changes in bone.

Who or what was studied?

The evidence includes pregnant women and mouse experiments. A human calcium-absorption study had only five women in its absorption subset. Other research examined vitamin D supplementation, abnormal vitamin D breakdown in mice and mouse responses to phosphate diets.

What did the studies find?

Human calcium absorption increased in the small study. Mice lacking a vitamin D breakdown enzyme had greater calcium absorption and high blood calcium. Separate mouse experiments found phosphate-related hormone responses without measuring maternal vitamin D. A human bone-marker analysis found that the marker rose in both treatment groups, despite a difference in one adjusted comparison.

What are the limits?

Animal findings do not establish a human supplement dose. The reviewed account reports no direct clinical measurements of phosphate absorption during human pregnancy. Blood minerals and bone markers cannot prove maternal bone protection or fewer fractures. The evidence shows adaptation, but leaves important questions about mechanisms and health outcomes unresolved.

Read the full article below ↓

Pregnancy creates calcium and phosphate demands as the fetal skeleton accumulates mineral. Vitamin D participates in this physiology, but a blood concentration alone cannot show how much mineral was absorbed, lost through the kidneys or retained in bone. This review separates direct human observations, animal experiments and biochemical trial findings to explain what is established and what remains uncertain. For the shorter account, read Vitamin D, Calcium, Phosphate and Skeletal Demands in Pregnancy: Study Summary.

Mineral demand is not the same measurement as blood concentration

Calcium and phosphate are both components of skeletal mineral. Meeting fetal demand involves maternal mineral supply and handling, not simply a higher number in a blood test. The reviewed Endotext account describes pregnancy-specific changes in intestinal absorption, renal handling and skeletal physiology. These processes must be assessed separately because a regulated circulating concentration can coexist with changing mineral movement between compartments.

Vitamin D and Calcium Physiology introduces the general calcium system, while Vitamin D and Phosphate Regulation explains phosphate regulation. Neither general account should be treated as proof that every pathway behaves identically during pregnancy. Gestational changes, nutrient availability and hormonal conditions affect how a result should be interpreted. A measurement of blood calcium is not a direct balance study, and a measurement of phosphate excretion is not a measurement of intestinal phosphate absorption.

The distinction also applies to vitamin D itself. Researchers may measure the status marker 25-hydroxyvitamin D or the active hormone, calcitriol. Giving vitamin D3 is a different intervention from deleting an enzyme that normally breaks down vitamin D metabolites. Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D explains the blood markers; Vitamin D Metabolism at the Cellular Level explains activation and degradation at the cellular level. Keeping these processes separate prevents an abnormal animal model from becoming an implied human supplementation instruction.

Human calcium absorption: direct evidence from a very small subset

Cross and colleagues followed women through pregnancy, lactation and the period after weaning. Twelve women entered the study, ten pregnancies were included in analysis, and nine women were followed postpartum. The study assessed biochemical markers, urinary mineral excretion and forearm bone mineral density, with direct calcium-absorption measurements in a much smaller subset.

The absorption observations are especially informative because they concern intestinal uptake rather than a circulating proxy. Mean fractional absorption was about 36% before pregnancy, 40% in the first trimester, 56% in the second and 62% in the third. The first-trimester difference was not significant; the later differences were. However, only five women contributed to the absorption subset, and only four had late-pregnancy observations. This is direct but imprecise evidence. It cannot establish the average magnitude of adaptation in every population or identify vitamin D as its sole cause.

Urinary calcium increased during pregnancy. Pregnancy phosphate excretion did not show a significant change, and the forearm measurement did not show a significant period effect. These results answer different questions. Increased absorption does not mean all absorbed calcium remained in maternal bone. An unchanged forearm measurement does not prove that the whole skeleton was unchanged. A nonsignificant phosphate-excretion comparison does not establish unchanged phosphate balance.

The cohort was small and selected, with high calcium intake, prenatal supplements, attrition, seasonal exposure and older analytical methods. Treatment groups were pooled after no difference was detected, and conflicting treatment counts in the report prevent a reliable treatment-specific interpretation here. The study supports a cautious description of maternal adaptation, not a dose-response conclusion or a precise allocation of fetal calcium between diet and maternal skeleton.

Vitamin D catabolism: a causal experiment in mice

Maekawa and colleagues studied mice lacking CYP24A1, the enzyme involved in vitamin D metabolite breakdown, and compared them with related wild-type animals. The experiment examined pregnancy, lactation and recovery after weaning. Measurements included calcium absorption, hormones, serum and urinary minerals, bone imaging and structural outcomes. This experimental alteration provides stronger causal information about the enzyme than an observational blood-level comparison.

During pregnancy, the enzyme-deficient mice had higher calcitriol, increased intestinal calcium absorption, high blood calcium and increased urinary calcium. Parathyroid hormone was suppressed and FGF23 was higher. Parathyroid hormone and FGF23 are hormones involved in mineral regulation. The combination shows that disrupting vitamin D breakdown can change several linked components of maternal calcium physiology.

The model does not establish what additional vitamin D does in a normal human pregnancy. A lifelong, whole-body inability to break down metabolites is not the same exposure as a supplement. It also does not establish that every adaptation requires vitamin D receptor signalling. The abstract of Fudge and Kovacs’ earlier receptor-null experiment reports pregnancy-related absorption and mineralization despite absence of the receptor. That principal paper was unavailable for full assessment, so its detailed results are not used here. Its contrary direction nevertheless prevents a universal receptor-necessity claim.

Maekawa’s phosphate results need particular restraint. Intestinal phosphate absorption was not measured. Expression of transport-related genes cannot substitute for an absorption measurement. Urinary phosphate relative to creatinine did not show a significant change. A separate measure (the fraction of filtered phosphate lost in urine) was higher in the enzyme-deficient mice during pregnancy. That comparison included only two enzyme-deficient animals, so the estimate is particularly uncertain. Normal serum phosphate likewise does not prove normal movement of phosphate through the body.

The skeletal findings also differed by period and measurement. Overall pregnancy bone-content gain was not significantly different between groups. Some lactation measurements suggested less loss in enzyme-deficient mice, but not every structural measure showed the same pattern. Pregnancy and lactation must therefore remain separate physiological states. Delivery difficulties requiring humane endpoints in some deficient animals further limit any claim that altered catabolism is simply beneficial or safe.

Phosphate deserves its own evidence

Calcium findings cannot stand in for phosphate physiology merely because the two minerals occur together in bone. The reviewed Endotext chapter makes an important distinction: increased phosphate absorption during pregnancy has been documented in rodents and other mammals, but it reports no clinical human pregnancy absorption studies. A broad statement that pregnancy doubles absorption must not be transferred from animal evidence to humans without that qualification.

Human FGF23 findings described in that account are also inconsistent across studies. A higher concentration in one cohort and no change in another do not establish a universal gestational pattern. Renal phosphate handling, intestinal uptake, dietary supply and skeletal demand are related but distinct processes. The available evidence does not justify inferring an exact human phosphate flux from a hormone concentration or an animal transporter result.

Sellars and colleagues provide direct experimental observations of maternal phosphate regulation in mice. One experiment compared dietary phosphate conditions in wild-type females before pregnancy and near term. A second used females carrying one altered Fgf23 gene copy. The maternal measurements were serum phosphorus, FGF23 and parathyroid hormone; the experiments did not measure maternal vitamin D metabolites, renal clearance, intestinal absorption or skeletal mineral balance.

Higher dietary phosphate produced higher maternal phosphorus and FGF23 in the wild-type experiment. Parathyroid hormone did not show a dietary response and was below detection during pregnancy in those wild-type mothers. In the second experiment, the FGF23 response was again detected, while the phosphorus difference was not statistically significant. Pregnancy parathyroid hormone remained low but detectable there. The two models therefore should not be described as having identical results.

These experiments show a maternal phosphate-responsive hormonal system under the tested conditions. They do not demonstrate a vitamin D-specific cause, the necessity of maternal FGF23, or the safety of a phosphate-loading diet. Group sizes were small, and assigning assay values at detection boundaries affects interpretation of apparently absent hormone concentrations. The maternal observations are useful for this review even though the original paper’s central question concerned fetal mineral regulation.

Maekawa and Sellars are separate experiments, but both come from the same research programme. They are not independent-laboratory replications. The Endotext account shares an author with that programme and supplies secondary physiological context rather than another primary confirmation. Recognizing these relationships prevents the number of publications from exaggerating the diversity of the evidence.

Human supplementation: biochemical response without a bone-protection result

Hollis and colleagues randomized pregnant women to different vitamin D3 regimens beginning around 12 to 16 weeks. Higher assigned exposure raised 25-hydroxyvitamin D. Across the reported comparisons, serum calcium, creatinine, phosphorus and urinary calcium-to-creatinine measurements did not show significant between-group differences. The study’s main question was biochemical status, not a direct test of maternal bone balance or fracture prevention.

Those findings should not be enlarged into proof that supplementation has no effect on any mineral process. The study did not measure all the processes discussed above, and incomplete follow-up, adherence and population selection constrain inference. Conversely, a higher status-marker concentration is not evidence that maternal bone was protected. Vitamin D Status vs Vitamin D Effect explains why measured status and physiological effect are separate questions.

Research exposure in this trial is not a personal regimen. Monitored trial participants and the timing of supplementation do not establish universal safety, particularly for unstudied populations or earlier pregnancy. The study contributes a human biochemical comparison to this review; it does not validate an animal mechanism in humans or resolve the source of fetal skeletal mineral.

Turnover markers add information, but do not measure fractures

Curtis and colleagues examined maternal bone turnover within the MAVIDOS trial. This was a post hoc analysis of the same underlying trial used for the neonatal bone report, not a separate trial confirming it. The Southampton subset compared vitamin D3 at 1,000 international units daily with placebo. Urinary CTX, a marker related to bone breakdown, was measured around 14 and 34 weeks and adjusted for urinary creatinine. The paired analysis included 372 women: 188 assigned placebo and 184 assigned vitamin D3. These amounts describe research exposure, not personal treatment instructions. Maternal bone imaging was performed shortly after delivery.

Both randomized groups showed an absolute rise in CTX. The standardized conditional-change treatment contrast was about −0.32 standard deviations, with a 95% confidence interval of −0.52 to −0.11. The comparison of absolute changes was not statistically significant (P=.19). A negative conditional value therefore must not be described as an absolute fall in bone breakdown. The all-available late-pregnancy comparison and the paired-sample comparison also had different results because they used different participant sets.

Higher late-pregnancy CTX was associated with some lower postpartum bone measurements. These were observational associations within the trial. Without a pre-pregnancy scan, they do not demonstrate how much bone an individual lost because of pregnancy. No fracture outcome was established. Bone Mineralisation, Turnover and Fractures Measure Different Outcomes explains why turnover, mineralization, imaging and fractures must remain distinct; Hormone Concentration, Receptor Response and Clinical Benefit makes the related distinction between a hormonal measurement and clinical benefit.

The principal report’s sample counts do not fully reconcile, and the material supplementary selection and height-adjusted analyses were unavailable. Those gaps prevent claims that selection bias was excluded or that a robust size-independent maternal bone benefit was demonstrated. Kidney handling, sampling conditions, nonmaternal contributions to turnover markers and multiple post hoc comparisons add further uncertainty. These limitations belong beside the finding, not only in a reference note.

Interpreting the whole mineral response

EvidenceDirect contributionImportant boundary
Cross: human longitudinal observationsSmall direct calcium-absorption subsetNot complete mineral balance or proof of vitamin D causation
Maekawa: enzyme-deficient miceExperimental change in calcium handlingAbnormal catabolism, not human supplementation
Sellars: mouse phosphate experimentsMaternal phosphate and hormone responsesMaternal vitamin D and absorption not measured
Hollis: human randomized exposureStatus response and mineral-marker comparisonsNot a maternal skeletal-outcome trial
Curtis: MAVIDOS secondary analysisTurnover and postpartum imaging associationsSame underlying trial; selection and endpoint limits

Pregnancy involves real mineral demands and measurable adaptation. The evidence supports increased human calcium absorption in a small direct study, experimentally altered calcium handling in mice, and phosphate-responsive maternal hormone measurements in mice. It also shows why unchanged blood minerals or improved vitamin D status cannot settle the question of maternal skeletal cost. Human phosphate absorption during pregnancy remains a particularly important uncertainty in the reviewed account.

This is a selected physiological evidence review, not a treatment guideline. It preserves affirmative findings without treating every pathway as established in humans. Adequate interpretation requires the mineral, compartment, pregnancy stage, study design and measured outcome to be specified together. A conclusion about one of these should not silently become a conclusion about all of them.

Sources and access

Full principal sources and claim-relevant material were assessed for Cross, Maekawa, Sellars and Hollis. Cross’s uninspected graphs are not used for additional estimates. Curtis’s final principal and main figures were inspected, but unavailable selection and height-adjustment supplements restrict its interpretation. Fudge is explicitly abstract-level contrary context. Endotext supplies reviewed pregnancy physiology, not an additional primary study.

Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: a longitudinal study. Cross NA et al. American Journal of Clinical Nutrition. 1995;61:514 to 523.

Maternal loss of 24-hydroxylase causes increased intestinal calcium absorption and hypercalcemia during pregnancy but reduced skeletal resorption during lactation in mice. Maekawa AS et al. Journal of Bone and Mineral Research. 2024;39:1793 to 1808.

Murine Fetal Serum Phosphorus is Set Independent of FGF23 and PTH, Except in the Presence of Maternal Phosphate Loading. Sellars KB et al. Endocrinology. 2021;162:bqaa202.

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness. Hollis BW et al. Journal of Bone and Mineral Research. 2011;26:2341 to 2357. Correction: Erratum: Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness. 2011.

Bone turnover in pregnancy, measured by urinary CTX, is influenced by vitamin D supplementation and is associated with maternal bone health: findings from the Maternal Vitamin D Osteoporosis Study (MAVIDOS) trial. Curtis EM et al. American Journal of Clinical Nutrition. 2021. Secondary analysis of MAVIDOS.

Pregnancy up-regulates intestinal calcium absorption and skeletal mineralization independently of the vitamin D receptor. Fudge NJ, Kovacs CS. Endocrinology. 2010;151:886 to 895. Abstract inspected; full principal unavailable.

Calcium and Phosphate Metabolism and Related Disorders During Pregnancy and Lactation. Kovacs CS. Endotext. Updated 12 October 2024. Relevant pregnancy and FGF23-disorder sections assessed; not the entire chapter.

Related reading

Original sources

Source

Maternal loss of 24-hydroxylase causes increased intestinal calcium absorption and hypercalcemia during pregnancy but reduced skeletal resorption during lactation in mice

Published in Maekawa AS et al. Journal of Bone and Mineral Research (2024).

Publication details

Maternal loss of 24-hydroxylase causes increased intestinal calcium absorption and hypercalcemia during pregnancy but reduced skeletal resorption during lactation in mice. Maekawa AS et al. Journal of Bone and Mineral Research. 2024;39:1793 to 1808.

Read more →
Source

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness

Published in Hollis BW et al. Journal of Bone and Mineral Research (2011).

Publication details

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness. Hollis BW et al. Journal of Bone and Mineral Research. 2011;26:2341 to 2357. Correction: Erratum: Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness. 2011.

Read more →
Source

Erratum: Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness.

Publication details

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness. Hollis BW et al. Journal of Bone and Mineral Research. 2011;26:2341 to 2357. Correction: Erratum: Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness. 2011.

Read more →
Source

Bone turnover in pregnancy, measured by urinary CTX, is influenced by vitamin D supplementation and is associated with maternal bone health: findings from the Maternal Vitamin D Osteoporosis Study (MAVIDOS) trial

Published in Curtis EM et al. American Journal of Clinical Nutrition (2021).

Publication details

Bone turnover in pregnancy, measured by urinary CTX, is influenced by vitamin D supplementation and is associated with maternal bone health: findings from the Maternal Vitamin D Osteoporosis Study (MAVIDOS) trial. Curtis EM et al. American Journal of Clinical Nutrition. 2021. Secondary analysis of MAVIDOS.

Read more →